Company profile
Abpro Holdings, Inc.
OTC: ABPO · Healthcare · Biotechnology
#1009 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
14DFH 14DQ 12GM —SS 17
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$2.9M
Employees
3
as of 2026-08-26
Market cap
$654.7k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$183.0k$183.0k2024
Net income-$2.9M-$2.9M2025
Operating income-$8.5M-$8.5M2025
Total assets$1.1M$1.1M2025
Liabilities$19.6M$19.6M2024
Equity-$8.8M-$8.8M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Abpro Holdings, Inc.’s revenue?
Abpro Holdings, Inc. booked $183.0k in FY2024 revenue, growing 50% year over year — faster than most Healthcare companies we track, at a -1580.3% net margin.
Peers · Healthcare
aTyr Pharma, Inc.36DHemp, Inc——NuGen Medical Devices Inc.24DPharmaRoth Labs, Inc.——Panacos Pharmaceuticals, Inc.——Appili Therapeutics Inc28DNeighbors
Middlesex →Key facts
CEOJin Wook Suk
SectorHealthcare
IndustryBiotechnology
HeadquartersWoburn, MA
ExchangeOTC: ABPO
Employees3
IPO date2022-03-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.